SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-028546
Filing Date
2023-08-14
Accepted
2023-08-14 16:35:02
Documents
65
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 773378
2 ex31-1.htm EX-31.1 25563
3 ex31-2.htm EX-31.2 27463
4 ex32-1.htm EX-32.1 9012
5 ex32-2.htm EX-32.2 8630
  Complete submission text file 0001493152-23-028546.txt   3947592

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cing-20230630.xsd EX-101.SCH 33043
7 XBRL CALCULATION FILE cing-20230630_cal.xml EX-101.CAL 55524
8 XBRL DEFINITION FILE cing-20230630_def.xml EX-101.DEF 125562
9 XBRL LABEL FILE cing-20230630_lab.xml EX-101.LAB 257119
10 XBRL PRESENTATION FILE cing-20230630_pre.xml EX-101.PRE 208446
59 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 475464
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

IRS No.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40874 | Film No.: 231171178
SIC: 2834 Pharmaceutical Preparations